A PATIENT GUIDE FROM BELLYMD

PEA: What the evidence actually shows.

A plain-language look at palmitoylethanolamide, the fatty molecule your body already makes, and what the published research does and does not support.

About this guide. PEA is one of eight ingredients in *MGB+ Clear*, dosed at 300 mg per daily serving. This handout covers the published evidence behind PEA so you can read it yourself and decide what makes sense for you.

CHAPTER ONE

What is PEA?

> *A short answer first. PEA is a fatty molecule your body makes on its own. It sits inside the system that tells your nerves and immune cells when to calm down. Most people have never heard of it, even though it has been studied for more than fifty years.*

PEA stands for *palmitoylethanolamide*. The body builds it from two simple parts: a common fatty acid called palmitic acid, and a small molecule called ethanolamine. Cells release PEA on demand, especially when tissue is stressed, irritated, or inflamed. In other words, it is not a foreign substance. It is part of how your body manages discomfort and inflammation in the background.[1,2]

Researchers first noticed PEA in the 1950s when they found that egg yolk, peanut oil, and soy lecithin all reduced fever and inflammation in lab studies. The active piece turned out to be PEA.[2] Decades later, the Nobel laureate Rita Levi-Montalcini and her colleagues showed that PEA quiets down a type of immune cell called the mast cell, which sits near nerves and releases inflammatory signals when it gets activated.[3,4]

Today, PEA is sold in Europe as a medical food and in the United States as a dietary supplement. It has been tested in dozens of clinical trials covering chronic pain, nerve pain, gut pain, fibromyalgia, and pelvic pain.[1,5,6,7]

> **THE SHORT VERSION**
> Your body already makes PEA. Taking PEA as a supplement raises the amount available so the system that normally calms inflammation and pain signals has more to work with.

Why most people have not heard of PEA

Two reasons. First, PEA is not a drug. It cannot be patented as a new chemical, so no large drug company has spent the money required to push it through US-style approval. Second, most of the research has been done in Italy, Spain, and the Netherlands, which means the trials are real and PubMed-indexed but the marketing reach in North America has been small.[1,5]

The result is a molecule with a respectable body of evidence and very little name recognition. That gap is closing as more reviews and meta-analyses are published.[6,7,8]

CHAPTER TWO

How PEA works in your body

> *Think of PEA as a signal that tells overactive immune cells and irritated nerves to settle down. It does not block pain the way ibuprofen does. It changes the volume on the alarm system itself.*

The thermostat analogy

Imagine your nervous system has a thermostat for how loudly it announces pain and inflammation. When tissue is injured or stressed, the thermostat ticks up. PEA is one of the molecules your body releases to tick it back down. Researchers call this an *autacoid local injury antagonism* mechanism, or ALIA for short. In plain language: a built-in, made-on-demand brake on inflammation.[3,4]

Where PEA acts

PEA does not have one single target. It works on several at the same time, which is part of why researchers find it interesting.

1. PPAR-alpha (the main lever)

PEA binds to a receptor inside cells called PPAR-alpha, short for peroxisome proliferator-activated receptor alpha. You can think of PPAR-alpha as a master switch that controls inflammation genes. When PEA flips that switch, cells make fewer of the messengers that drive swelling, soreness, and nerve hypersensitivity.[9,5]

2. Mast cells (the immune-system alarm bells)

Mast cells are immune cells that release histamine and other inflammatory signals when triggered. They cluster near nerves, especially in the gut and skin. PEA stabilizes these cells so they release less of their cargo when something stresses them.[3,4,10]

3. The endocannabinoid system (the entourage effect)

Your body has its own cannabinoid system, separate from anything related to marijuana. PEA does not bind cannabinoid receptors directly. Instead, it slows the breakdown of the body's own cannabinoid molecules, leaving more of them available. This indirect boost is sometimes called the *entourage effect*. The result is a calmer pain and inflammation signal.[5,10]

4. Glial cells (the spinal-cord support staff)

Glia are support cells around nerves. When pain becomes chronic, glia get stuck in an activated state and keep amplifying signals long after the original injury is gone. PEA helps quiet these cells, which is the mechanism researchers point to when discussing pain from oversensitive nerves rather than actual tissue damage, a state sometimes called *nociplastic pain*.[4,11,12]

> **WHY THIS MATTERS FOR SYMPTOM CLUSTERS**
>
> Bloating, brain fog, fatigue, and headache often travel together because they share an oversensitive signaling system, not because they share a single cause. PEA acts on that signaling system at multiple points. That is the reason it shows up in research on conditions as different as fibromyalgia, irritable bowel syndrome, sciatica, and pelvic pain.

What PEA is not

PEA is not an opioid. It does not bind opioid receptors. It is not a benzodiazepine. It does not cross into the brain the way alcohol or sedatives do. It does not block prostaglandins the way ibuprofen and naproxen do, which is why it does not carry the stomach-ulcer or kidney risks those drugs do.[1,5]

CHAPTER THREE

What the studies show

> *Here is the published evidence by condition. Honest about what is strong, what is preliminary, and where the data has limits. Every claim links to a real, PubMed-indexed paper listed in the references at the back of this guide.*

Chronic pain, taken as a whole

META-ANALYSES · THOUSANDS OF POOLED PATIENTS

Two large meta-analyses have pooled data from PEA trials in different pain conditions. A 2017 meta-analysis in *Pain Physician* combined data from twelve studies and found that PEA reduced pain scores significantly more than placebo.[7] A 2023 systematic review in *Nutrients* looked only at double-blind randomized trials and reached a similar conclusion: PEA reduced pain across diverse conditions, with a favorable safety profile and small-to-moderate effect sizes.[8]

What this means in plain English: when researchers add up many studies, PEA consistently beats placebo for pain, but the size of the benefit varies and is not dramatic in every individual study.

Sciatica and chronic low back pain

LARGEST TRIAL · 636 PATIENTS

The largest controlled trial of PEA enrolled 636 people with low back pain and sciatica, the nerve pain that radiates down a leg from a compressed spinal nerve. Patients took either 300 mg or 600 mg of PEA daily or a placebo for three weeks. A later post-hoc analysis in *CNS & Neurological Disorders Drug Targets* reported a number-needed-to-treat of about 1.7 for meaningful pain relief at the 600 mg dose, which is a strong result for a non-drug intervention.[13]

What this means: in a study that is large by supplement-trial standards, PEA reduced sciatica pain noticeably better than placebo. The 300 mg arm also improved, just less than the 600 mg arm.

Diabetic peripheral neuropathy

RECENT RANDOMIZED TRIAL · 70 PATIENTS

Diabetic neuropathy is nerve damage in the feet and legs caused by long-term high blood sugar. It produces burning, tingling, or shooting pain that is famously hard to treat. A 2022 randomized, placebo-controlled trial in *Inflammopharmacology* tested 600 mg of PEA daily against placebo for eight weeks in 70 patients with diabetic neuropathic pain. The PEA group had significantly lower pain scores and significantly less pain interference with daily life.[14]

An earlier open-label trial in *Pain Research and Treatment* used 1,200 mg of ultramicronized PEA for 40 days as an add-on to existing therapy. Average pain scores dropped from 8.2 out of 10 to 5.8 out of 10.[15] A separate study by Schifilliti and colleagues reported similar improvement at 600 mg.[16]

What this means: for a condition where standard drugs are only partially effective and often poorly tolerated, PEA has held up across multiple small trials. The 2022 study is the strongest because it was placebo-controlled and double-blind.

Carpal tunnel syndrome

RANDOMIZED STUDY · NERVE-CONDUCTION ENDPOINT

Carpal tunnel syndrome is compression of a nerve at the wrist that causes hand pain, numbness, and tingling. A 2011 randomized study in *Minerva Medica* tested PEA against placebo in moderate carpal tunnel and showed not only symptom improvement but measurable improvement on nerve-conduction testing, which is the objective electrical measure neurologists use.[17]

Irritable bowel syndrome and visceral pain

RANDOMIZED TRIALS · ADULT AND PEDIATRIC

Irritable bowel syndrome (IBS) is a disorder of gut-brain communication. The hallmark is an oversensitive gut, meaning normal amounts of gas or stretching produce abnormal amounts of pain.

A 2017 randomized, double-blind, placebo-controlled multicenter trial in *Alimentary Pharmacology & Therapeutics* tested PEA combined with a related molecule called polydatin in 54 adults with IBS. Compared with placebo, the combination meaningfully reduced abdominal pain severity over twelve weeks.[18]

A 2024 pediatric trial in *Nutrition* applied the same PEA-polydatin combination to children and teenagers with IBS (ages 10 to 17) using Rome IV criteria. PEA-polydatin again reduced abdominal pain compared with placebo, with no safety concerns.[19]

What this means: PEA has direct, double-blind evidence in IBS, both adult and pediatric. The trials are not huge, but the design is rigorous.

Fibromyalgia

OBSERVATIONAL STUDIES · HUNDREDS OF PATIENTS

Fibromyalgia is a chronic-pain condition built around pain from oversensitive nerves rather than actual tissue damage, accompanied by fatigue, poor sleep, and brain fog.

A 2015 prospective and retrospective study in *Pain and Therapy* followed 80 patients on duloxetine and pregabalin. Adding PEA produced significantly greater pain reduction than the two prescription drugs alone.[20] A 2019 retrospective study in *CNS & Neurological Disorders Drug Targets* reviewed 407 fibromyalgia patients prescribed ultramicronized PEA as add-on therapy and reported meaningful improvement in pain scores.[21]

What this means: the fibromyalgia evidence is mostly observational rather than placebo-controlled. The signal is consistent across multiple studies and clinicians, but no large blinded trial has been done.

Pelvic pain and endometriosis

PILOT STUDIES · PEA-POLYDATIN COMBINATION

A small 2010 pilot study in the *European Journal of Obstetrics, Gynecology, and Reproductive Biology* gave PEA combined with polydatin to women with endometriosis-associated chronic pelvic pain. Pain dropped meaningfully within one month, and the women reduced their use of standard pain medication.[22] A 2015 randomized trial in *Journal of Pediatric and Adolescent Gynecology* tested the same combination in young women with primary dysmenorrhea (painful periods) and reported lower pain than placebo.[23]

What this means: pelvic-pain evidence is preliminary, mostly from small trials using a fixed combination product. The direction is consistent. Larger trials are needed before strong claims are appropriate.

Central sensitization (a closer look at mechanism)

EXPERIMENTAL TRIAL · HEALTHY VOLUNTEERS

A 2022 randomized, double-blind, placebo-controlled crossover study in *Nutrients* took healthy volunteers, used standardized lab techniques to create central sensitization (an artificial state in which the nervous system becomes oversensitive to touch and pressure), and tested whether PEA reduced it. PEA significantly reduced central sensitization and modulated how participants processed pain.[12]

What this means: this is the clearest experimental evidence that PEA acts on the central nervous-system sensitization mechanism, not just on peripheral inflammation.

CHAPTER FOUR

About dose and timing

> *Published trials have used 300, 600, and 1,200 mg per day. Higher doses have been used in acute pain studies. Lower daily doses look reasonable as a maintenance choice. PEA usually takes weeks, not days, to reach full effect.*

What the literature has tested

DAILY DOSE	TYPICAL USE IN TRIALS	TIME TO EFFECT
300 mg	Maintenance arm in the 636-patient sciatica trial[13]	2 to 4 weeks for partial effect; longer for full effect
600 mg	Most randomized trials including diabetic neuropathy[14] and sciatica[13]	4 to 8 weeks for full effect
1,200 mg	Higher-intensity neuropathic pain trials[15,16]	2 to 6 weeks; used short-term in most studies

Why 300 mg is reasonable as a maintenance dose

The 636-patient sciatica trial showed that the 300 mg arm did improve, just less than the 600 mg arm.[13] Used as part of a multi-ingredient formulation aimed at everyday support rather than acute pain, 300 mg of PEA is a defensible foundation dose. People with significant pain should expect higher doses to be used in clinical research.

Time to effect

PEA is not an immediate-relief substance. In most studies, meaningful changes appear after roughly four to eight weeks of consistent daily use.[7,8] If you start taking PEA, set the expectation of a slow build. If you feel nothing in week one, that is normal.

Formulations

Studies have used three main forms: standard PEA, micronized PEA, and ultramicronized PEA. The smaller particle sizes are easier for the body to absorb.[5,8] Most trials reporting clear benefit have used micronized or ultramicronized PEA, so formulation does appear to matter.

CHAPTER FIVE

Safety and things to know

> *PEA has one of the cleaner safety profiles in the supplement literature. That is not a license for casual use. A few specific situations deserve attention.*

Side-effect profile

The 2016 review in the *British Journal of Clinical Pharmacology* looked across sixteen clinical trials, six case reports, and a meta-analysis. The conclusion: for treatment up to 49 days, the clinical data argue against serious adverse drug reactions at a rate of one in two hundred or higher.[1] In plainer terms, side effects are rare. When they do occur, the most common are mild gastrointestinal complaints, which usually resolve.

Drug interactions

There are no known major drug interactions with PEA. The molecule does not appear to interfere with the cytochrome P450 enzymes that handle most prescription medications.[1,5] That said, PEA has not been tested in every drug combination, so check with your physician if you take prescription medications, especially blood thinners, immunosuppressants, or chemotherapy agents.

Pregnancy and lactation

There is no controlled human data on PEA during pregnancy or breastfeeding. Animal studies have not raised flags, but absence of evidence is not the same as evidence of safety. The conservative recommendation is to avoid PEA during pregnancy and lactation unless a physician advises otherwise.

Pediatric use

The 2024 pediatric IBS trial used PEA in children aged 10 to 17 with no safety concerns over twelve weeks.[19] For younger children, evidence is limited and pediatric use should be physician-directed.

> **WHEN TO TALK TO YOUR PHYSICIAN FIRST**
>
> - You are pregnant or nursing.
> - You take prescription pain, blood-thinning, or immune-modulating medications.
> - You are managing a serious chronic condition such as cancer, diabetes, or autoimmune disease.
> - You are giving PEA to a child.

CHAPTER SIX

Where the evidence has limits

> *An honest brief includes the weaknesses of the science it cites. Here is where the PEA literature is thinner than the headlines suggest.*

Trial size

Most PEA trials enroll fewer than 100 patients. The sciatica trial is a notable exception with 636 patients.[13] Small trials can produce real signals, but they can also overestimate benefit. Larger blinded trials would strengthen the picture.

Industry funding and origin of trials

A significant portion of PEA research has been funded by or conducted in collaboration with companies that sell PEA products, especially in Italy. This does not invalidate the data, but it means independent replication outside that ecosystem is still relatively limited.[1,8]

Variability in formulation

Studies use standard, micronized, and ultramicronized forms. Findings from one form do not automatically transfer to another. Most positive trials used micronized or ultramicronized PEA.[5,8]

Long-term data

Most trials run between three weeks and three months. Long-term safety beyond several months is presumed reasonable based on the favorable short-term profile, but is not specifically proven by trial data.[1]

Honest summary

The strongest evidence is for nerve-related pain, especially sciatica and diabetic neuropathy, with smaller but consistent signals in IBS and pelvic pain. Fibromyalgia data is encouraging but mostly observational. Central-sensitization mechanism work is consistent. Where someone tells you PEA is a cure for anything, the evidence does not support that. Where someone tells you PEA is useless, the evidence does not support that either. The honest position is somewhere in between.

CHAPTER SEVEN

The bigger picture

> *Symptom clusters rarely have one cause. They usually share a mechanism. That is the thinking behind a multi-ingredient approach.*

When bloating, brain fog, fatigue, and headache travel together, the common thread is usually an oversensitive signaling system, not a single broken organ. Single-ingredient supplements aimed at one symptom often miss the underlying pattern. A formulation built around mechanism uses several ingredients that each act on a different lever of the same system.

PEA fits that thinking. It works on PPAR-alpha, mast cells, and glial-cell activation. Other ingredients in *MGB+ Clear* address adjacent layers: magnesium glycinate for muscle and nerve relaxation, allithiamine for nerve and brain energy metabolism, and additional compounds chosen for complementary mechanism rather than overlapping function.

The point is not that PEA does everything. It is that the evidence supports PEA as one capable lever among several. For people whose tests are normal but whose symptoms travel together, that mechanism-first thinking tends to age better than chasing one symptom at a time.

> **HOW TO USE THIS BRIEF**
>
> Bring it to your physician. Read the references. If you decide to try PEA, give it at least eight weeks at a consistent daily dose before judging effect, and track how you feel using whatever method works for you. Real data, your data, beats marketing claims from either side.

BellyMD · belly-md.com

CITATIONS

References

All references are PubMed-indexed. PMID numbers are listed for verification. Where assigned, DOIs are included for direct linking.

1. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. *Br J Clin Pharmacol.* 2016;82(4):932-942. *PMID: 27220803. doi:10.1111/bcp.13020*
2. LoVerme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol Pharmacol.* 2005;67(1):15-19. *PMID: 15465922. doi:10.1124/mol.104.006353*
3. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A.* 1995;92(8):3376-3380. *PMID: 7724569. doi:10.1073/pnas.92.8.3376*
4. Skaper SD, Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. *Philos Trans R Soc Lond B Biol Sci.* 2012;367(1607):3312-3325. *PMID: 23108549. doi:10.1098/rstb.2011.0391*
5. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. *Br J Pharmacol.* 2017;174(11):1349-1365. *PMID: 27539936. doi:10.1111/bph.13580*
6. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. *Pain Physician.* 2016;19(2):11-24. *PMID: 26815246*
7. Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. *Pain Physician.* 2017;20(5):353-362. *PMID: 28727699*
8. Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. *Nutrients.* 2023;15(6):1350. *PMID: 36986081. doi:10.3390/nu15061350*
9. De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T. New insights in mast cell modulation by palmitoylethanolamide. *CNS Neurol Disord Drug Targets.* 2013;12(1):78-83. *PMID: 23394523. doi:10.2174/1871527311312010013*
10. Keppel Hesselink JM, Hekker TAM. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. *J Pain Res.* 2012;5:437-442. *PMID: 23166447. doi:10.2147/JPR.S32143*
11. Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. *J Pain Res.* 2015;8:729-734. *PMID: 26604814. doi:10.2147/JPR.S93106*
12. Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The effect of palmitoylethanolamide on pain intensity, central and peripheral sensitization, and pain modulation in healthy volunteers: a randomized, double-blinded, placebo-controlled crossover trial. *Nutrients.* 2022;14(19):4084. *PMID: 36235736. doi:10.3390/nu14194084*
13. Cruccu G, Di Stefano G, Marchettini P, Truini A. Micronized palmitoylethanolamide: a post hoc analysis of a controlled study in patients with low back pain - sciatica. *CNS Neurol Disord Drug Targets.* 2019;18(6):491-495. *PMID: 31269891. doi:10.2174/1871527318666190703110036*
14. Pickering E, Steels EL, Steadman KJ, Rao A, Vitetta L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. *Inflammopharmacology.* 2022;30(6):2063-2077. *PMID: 36057884. doi:10.1007/s10787-022-01033-8*
15. Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. *Pain Res Treat.* 2014;2014:854560. *PMID: 24967102. doi:10.1155/2014/854560*
16. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. *Pain Res Treat.* 2014;2014:849623. *PMID: 24804094. doi:10.1155/2014/849623*
17. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. *Minerva Med.* 2011;102(2):141-147. *PMID: 21483401*
18. Cremon C, Stanghellini V, Barbaro MR, Cogliandro RF, Bellacosa L, Santos J, Vicario M, Pigrau M, Alonso Cotoner C, Lobo B, Azpiroz F, Bruley des Varannes S, Neunlist M, DeFilippis D, Iuvone T, Petrosino S, Di Marzo V, Barbara G. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. *Aliment Pharmacol Ther.* 2017;45(7):909-922. *PMID: 28164346. doi:10.1111/apt.13958*
19. Di Nardo G, Bernardo L, Cremon C, Barbara G, Felici E, Evangelisti M, Ferretti A, Furio S, Piccirillo M, Coluzzi F, Parisi P, Mauro A, Di Mari C, D'Angelo F, Mennini M. Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: a multicentric randomized controlled trial. *Nutrition.* 2024;122:112397. *PMID: 38479039. doi:10.1016/j.nut.2024.112397*
20. Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. *Pain Ther.* 2015;4(2):169-178. *PMID: 26334329. doi:10.1007/s40122-015-0038-6*

21. Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Balzo GD, Sarzi-Puttini P, Parolini M, Polati E. Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. *CNS Neurol Disord Drug Targets*. 2019;18(4):326-333. *PMID: 30827269. doi:10.2174/1871527318666190227205359*

22. Indraccolo U, Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. *Eur J Obstet Gynecol Reprod Biol.* 2010;150(1):76-79. *PMID: 20176435. doi:10.1016/j.ejogrb.2010.01.008*

23. Tartaglia E, Armentano M, Giugliano B, Sena T, Giuliano P, Loffredo C, Mastrantonio P. Effectiveness of the association N-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. *J Pediatr Adolesc Gynecol*. 2015;28(6):447-450. *PMID: 26233289. doi:10.1016/j.jpag.2014.12.011*

BellyMD · belly-md.com